Osteoporosis and heart disease represent a significant public health problem, with a substantial public health impact.

Recently published data on a special form of vitamin K2, called menaquinone-7 (MK7), demonstrated its unique effect and potential benefits on heart disease and bone metabolism. Vitamin K2 is emerging as a key factor in regulating calcium in the body.

Insufficient Vitamin K2 leads to decreased bone mineral density, a key factor in osteoporosis, and to an excess of calcium in the arterial wall, which increases the risk of heart disease.


Vitamk7® exclusively manufactured by Gnosis, is the active isomer of Vit K2 with the highest bioavailability and longest half-life in the blood. Clinical trials were performed by Gnosis on the effect of Vitamk7® on the gamma carboxylation of ostecalcin in vivo study, and on PGE-2 synthesis in bone forming osteoblasts in vitro study.

Vitamk7® is available in powder and in oil forms, suitable for different dosages and formulations. Obtained through a patented natural fermentation process, Vitamk7® is natural and solvent free, and consists entirely of all-trans vitamin K2.

Vitamk7® Powder

Vitamk7® Oil


For more information please visit www.vitamk7.com




GNOSIS S.P.A. Sede Legale: Piazza del Carmine, 4 20121 Milano. P. IVA 02484720129 C. F. 10197170151 Cap. Soc. 3.000.000,00 € i.v. Registro delle imprese di Milano N° 10197170151